Christian Hein · 18 November 2024 · 1 min read
Some really interesting news from Sanofi recently, in the hot AI in clinical trials space: Format...
Formation Bio, in collaboration with Sanofi and OpenAI, has introduced Muse, an AI-powered tool designed to optimize patient recruitment in clinical trials. I think it will be fascinating to watch how this three-party collaboration — Big Pharma, Health Tech, and Large Tech — evolves, and I wouldn't be surprised to see more of these partnerships emerge in the coming year.
Some really interesting news from Sanofi recently, in the hot AI in clinical trials space: Formation Bio, in collaboration with Sanofi and OpenAI, has introduced Muse, an AI-powered tool designed to optimize patient recruitment in clinical trials. Some interesting elements in there, like a dedicated LLM agent that incorporates Institutional Review Board and regulatory guidelines, and auto-generation of recruitment materials and pre-screening questionnaires.
In the bigger picture, it will be fascinating to watch how this three-party collaboration - Big Pharma, Health Tech, and Large Tech - evolves over time. Given the momentum in the sector, I wouldn't be surprised to see more of these partnerships emerge in the coming year as AI continues to reshape clinical operations and healthcare at large.
Filed under AI in Pharma · Tech Bio
Artificial Intelligence · Agentic AI · In-Silico Clinical Trials · Large Pharma · Health Tech · Partnership / Alliance · Clinical development
Related insights
18 Jun 2025
An interesting discussion on AI in drug discovery and development with Thirupathi Pattipaka from...
19 May 2026
The rise of agentic in drug R&D - Owkin & AZ
12 May 2026
Isomorphic about to raise $2bn - and why I'm not sure that's a good thing
31 Mar 2026
Eli Lilly and Insilico Medicine: what three AI drug discovery deals signal